SAN DIEGO, July 18, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Dr. Preston Klassen, President and Head of Research & Development of Regulus, will present at the H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 3:00 p.m. ET.
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.